Katherine D Crew, MD

Medical Oncology
Cancer Care, Internal Medicine
More specialties
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Overview

Katherine D. Crew, M.D., M.S. is an the Avon Products Foundation Professor of Medicine and Epidemiology at the NewYork-Presbyterian/Columbia University Medical Center, co-associate director for education and training and co-director of the Cancer Research Training and Education Core (CRTEC) at the Herbert Irving Comprehensive Cancer Center (HICCC). In addition to treating patients with breast cancer and women at high-risk for breast cancer, Dr. Crew has a long-standing interest and background in the design of clinical trials and observational studies in breast cancer prevention and survivorship.

She serves as the Director of the Clinical Breast Cancer Prevention Program at Columbia University and Executive Officer for the SWOG Prevention, Screening, and Surveillance and Cancer Care Delivery Committees. She is a member of multiple national consortia and societies in oncology, including the American Association for Cancer Research and American Society of Clinical Oncology, and is an editorial board member of the Journal of Clinical Oncology.

Dr. Crew received her undergraduate B.S. in Biochemistry from Brown University, where she graduated Magna Cum Laude. She received her M.D. from Columbia University College of Physicians and Surgeons and her M.S. from Columbia University School of Public Health. She completed her Internal Medicine residency and Medical Oncology fellowship at NewYork-Presbyterian/Columbia University Medical Center

Areas of Expertise / Conditions Treated

  • Breast Cancer
  • High Risk Breast Disease

Academic Appointments

  • Avon Products Foundation Professor of Medicine and Epidemiology

Administrative Titles

  • Director of Clinical Breast Cancer Prevention Program
  • Co-Director, Cancer Research Training and Education Core (CRTEC), HICCC
  • Co-Associate Director, Education and Training, HICCC
  • Director of Faculty Development, Division of Hematology/Oncology, CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Spanish

Gender

  • Female

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

AETNA

  • Aetna Signature Administrators
  • NYP Employee Plan
  • NY Signature
  • POS
  • Student Health

Affinity Health Plan

  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

CIGNA

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

VNSNY CHOICE

  • HMO
  • SelectHealth

WellCare

  • Medicare Managed Care
  • New Jersey Services (Medicaid Managed Care)

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MS, Columbia University Mailman School of Public Health
  • BS, Brown University
  • MD, 1999 Columbia University Vagelos College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Committees, Societies, Councils

National Committees:

  • Member, NewYork Presbyterian Hospital, Research IT Steering Committee
  • Executive Officer, SWOG Cancer Prevention, Screening, and Surveillance, Cancer Care Delivery Committees
  • Cancer Prevention and Control (CPC) Central Institutional Review Board (CIRB), National Cancer Institute, Division of Cancer Prevention
  • Chair, National Institutes of Health (NIH) Cancer Prevention Study Section

Memberships and Positions:

  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • SWOG Cancer Research Network
  • NCI, Division of Cancer Prevention Phase I/II Chemoprevention Trials Consortium

Editorial Board:

  • Journal of Clinical Oncology

Board Certifications

  • Internal Medicine
  • Medical Oncology

Honors & Awards

  • 2006-2010, NIH Loan Repayment Program Award
  • 2003-2005, Full Scholarship for Masters in Biostatistics, Patient Oriented Research Track, Mailman School of Public Health, Columbia University
  • 1996-1997, Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Laboratory of Chemoprevention, National Cancer Institute

Research

Dr. Crew’s research involves the development of early phase clinical trials for evaluating chemopreventive agents for breast cancer. These studies implement intermediate markers for breast cancer risk, such as mammographic density, tissue- and serum-based biomarkers. In a presurgical study design, women with newly diagnosed breast cancer are given a short-term drug administration during the interval between breast biopsy and surgical resection to test the biologic activity of the drug in breast tumor tissue. In the phase I/II setting, clinical trials of high-dose vitamin D and a green tea extract, Polyphenon E, in high-risk women have been conducted.

Dr. Crew also participates in multicenter breast cancer chemoprevention trials through the Phase I/II Chemoprevention Trials Consortium and the SWOG Cancer Research Network. The overall goal of this research is to build a comprehensive, interdisciplinary breast cancer prevention program, which will offer preventive strategies to breast cancer patients and healthy, high-risk women.

Dr. Crew is actively studying how to better identify women at high-risk for breast cancer in the primary care setting using patient-centered decision aids and provider-centered decision support tools embedded within the electronic health record. The overall goal of this work is to adopt risk-appropriate breast cancer screening and prevention strategies.

Research Interests

  • Breast Cancer
  • Clinical trials in breast cancer treatment and prevention

Grants

  • R01 CA293927
    Crew, Kukafka (MPIs)
    07/08/24-06/30/29
    Integrating breast cancer and cardiovascular disease risk to explore decision-making for chemoprevention among racially/ethnically diverse women at high risk for breast cancer
  • R01 CA226060
    Crew, Kukafka (MPIs)
    12/01/18-11/30/24
    Multicenter trial of decision support for breast cancer chemoprevention
  • R38 CA277850
    Crew, Kachnic (MPIs)
    03/01/24-02/28/29
    Columbia Cancer Research Training Program for Resident-Investigators (CAPRI)
  • P50 MD017341Terry, Shimbo, Williams, Phillips, Cohn, Hershman (multi-PIs)
    Role: co-investigator, core director
    07/01/21-06/30/26
    Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center)
  • U01 HG008680
    Weng (PI), Role: Co-Investigator
    04/01/20-03/31/25
    EHR-based genomic risk assessment and management for diverse populations

Selected Publications

  1. Crew, K.D., Capodice, J., Greenlee, H., Brafman, L., Fuentes, D., Awad, D., Hershman, D.L. (2010). Randomized, blinded, controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early stage breast cancer. Journal of Clinical Oncology.28:1154-1160.PMID: 201009632.
  2. Hershman, D.L., Unger, J.M., Greenlee, H., Capodice, J.L., Lew, D.L., Darke, A.K., Kengla, A.T.,Melnik, M.K., Jorgensen, C.W., Kreisle, W.H., Minasian, L.M., Fisch, M.J., Henry, N.L.,Crew, K.D.(2018). Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. JAMA.320:167-176. PMCID: PMC6583520
  3. McGuinness, J.E., Ro, V., Mutasa, S., Pan, S., Hu, J., Trivedi, M.S., Accordino, M.K., Kalinsky, K.,Hershman, D.L., Ha, R.S.,Crew, K.D.(2022). Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence amongwomen with hormone receptor-positive operable breast cancer. Breast Cancer Research and Treatment.194:35-47.PMID: 355759544.
  4. Kukafka, R., Pan, S., Silverman, T., Zhang, T., Chung, W.K., Terry, M.B., Fleck, E., Younge, R.G.,Trivedi, M.S., McGuinness, J.E.,He, T., Dimond, J.,Crew, K.D.(2022). Patient and clinician decision support to increase genetic counseling for hereditary breast and ovarian cancer syndrome in primary care: A cluster randomized controlled trial. JAMA Network Open.5:e2222092. PMCID: PMC9294997

Global Health Activities

The South African breast cancer and HIV outcomes (SABCHO) study: A multi-center cohort study of HIV and breast cancer in sub-Saharan Africa

Period: 10/01/15-09/31/20

Multi-PIs: Ruff P, Joffe M, Neugut A; Co-I: Crew KD

Funding Agency: National Cancer Institute – R01 CA192627-01